Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Paul G. Richardson, Alessandra Larocca et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 13
Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm StudyKatja Weisel, Paul G. Richardson, Meletios Α. Dimopoulos et al.|Blood|2018Cited by 1